EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neonatal Treatment with Astaxanthin-Loaded Stealth Solid Lipid Nanoparticles Activates the Impaired NRF2 Pathway and Reduces Hippocampal Oxidative Stress in a Mouse Model of Trisomy 21

Laura Angelozzi, Debora Santonocito iD, Francesca Flotta iD, Beatrice Uguagliati iD, Marco Emili, Noemí Rueda Revilla iD, Carmen Martínez-Cué iD, Carmelo Puglia iD, Fiorenza Stagni iD, Sandra Guidi iD

Cells · 19.08.2026 · 15 (16) · 1495

DOI: 10.3390/cells15161495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 19.08.2026. Verfasst von Laura Angelozzi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department for Life Quality Studies, University of Bologna, 47921 Rimini, Italy. Hauptthemen laut MEDLINE: Oxidative Stress, NF-E2-Related Factor 2, Hippocampus, Nanoparticles. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Monte di Bologna and Ravenna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oxidative stress is an important contributor to brain abnormalities in Down syndrome (DS), but the status of the nuclear factor erythroid 2-related factor 2 (NRF2) antioxidant pathway during early postnatal development remains poorly understood. The current study aimed to investigate whether an impairment of the NRF2 pathway is already present in the Ts65Dn mouse model of trisomy 21 at neonatal life stages and whether early treatment with astaxanthin-loaded stealth solid lipid nanoparticles (AST-SSLNs) positively impacts NRF2 signaling and reduces oxidative stress.

Methods

Hippocampal NRF2 pathway components and oxidative stress markers were analyzed in neonate Ts65Dn and euploid mice. From postnatal day (P)3 to P15, mice received daily subcutaneous injections of AST-SSLNs or unloaded nanoparticles. NRF2 pathway activation, reactive oxygen species (ROS), lipid peroxidation, protein carbonylation, and safety parameters were evaluated.

Results

Untreated Ts65Dn mice exhibited early impairment of the NRF2 pathway, characterized by increased BACH1, reduced NRF2 activation, and decreased HO-1 expression. Neonatal AST-SSLN treatment enhanced NRF2 activation, improved HO-1 levels, and normalized ROS accumulation, lipid peroxidation, and protein carbonylation in the hippocampus, a brain region critically impaired in DS. Treatment had no adverse effects on survival, body weight, or brain weight.

Conclusions

These findings demonstrate that NRF2 pathway dysfunction is an early event in trisomy 21 and identify the neonatal period as a potential therapeutic window to counteract oxidative stress. AST-SSLNs represent a promising nanomedicine-based strategy to activate the impaired NRF2 pathway and reduce early hippocampal oxidative damage in DS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oxidative StressNF-E2-Related Factor 2HippocampusNanoparticlesDown SyndromeLipidsAnimalsXanthophyllsDisease Models, AnimalMiceAnimals, NewbornSignal TransductionReactive Oxygen SpeciesMale

Stichwörter der Autor:innen

Down syndromeNRF2 pathwayastaxanthinoxidative stress

Substanzen

astaxanthineNF-E2-Related Factor 2XanthophyllsReactive Oxygen SpeciesLipidsNfe2l2 protein, mouse

Autor:innen und Institutionen

  • Department for Life Quality Studies, University of Bologna, 47921 Rimini, Italy.
  • Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
  • Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.
  • Department of Physiology and Pharmacology, University of Cantabria, 39005 Santander, Spain.

ORCID-Profile: Debora Santonocito, Francesca Flotta, Beatrice Uguagliati, Noemí Rueda Revilla, Carmen Martínez-Cué, Carmelo Puglia, Fiorenza Stagni, Sandra Guidi

Förderung

  • Fondazione Monte di Bologna and Ravenna

Zitieren

APA

Angelozzi, L., Santonocito, D., Flotta, F., Uguagliati, B., Emili, M., Rueda Revilla, N., Martínez-Cué, C., Puglia, C., Stagni, F., & Guidi, S. (2026). Neonatal Treatment with Astaxanthin-Loaded Stealth Solid Lipid Nanoparticles Activates the Impaired NRF2 Pathway and Reduces Hippocampal Oxidative Stress in a Mouse Model of Trisomy 21. Cells, 15(16), 1495. https://doi.org/10.3390/cells15161495

Vancouver

Angelozzi L, Santonocito D, Flotta F, Uguagliati B, Emili M, Rueda Revilla N, et al. Neonatal Treatment with Astaxanthin-Loaded Stealth Solid Lipid Nanoparticles Activates the Impaired NRF2 Pathway and Reduces Hippocampal Oxidative Stress in a Mouse Model of Trisomy 21. Cells. 2026;15(16):1495. doi:10.3390/cells15161495

BibTeX
@article{Angelozzi2026,
  author = {Angelozzi, Laura and Santonocito, Debora and Flotta, Francesca and Uguagliati, Beatrice and Emili, Marco and Rueda Revilla, Noemí and Martínez-Cué, Carmen and Puglia, Carmelo and Stagni, Fiorenza and Guidi, Sandra},
  title = {Neonatal Treatment with Astaxanthin-Loaded Stealth Solid Lipid Nanoparticles Activates the Impaired NRF2 Pathway and Reduces Hippocampal Oxidative Stress in a Mouse Model of Trisomy 21},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {1495},
  doi = {10.3390/cells15161495}
}
Kostenlos starten →